4-氨基-2-(4-吗啉基)-5-嘧啶甲腈 | 78318-43-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-氨基-2-(4-吗啉基)-5-嘧啶甲腈
• 中文别名: 4-氨基-2-吗啉-5-嘧啶甲腈
• 英文名称: 4-Amino-2-morpholino-pyrimidin-5-carbonitril
• 英文别名: 4-amino-2-(4-morpholinyl)-5-pyrimidinecarbonitriIe；4-Amino-2-(4-morpholinyl)-5-pyrimidinecarbonitrile；4-amino-2-morpholin-4-ylpyrimidine-5-carbonitrile
• CAS: 78318-43-1
• 化学式: C₉H₁₁N₅O
• 分子量: 205.219
• InChiKey: ICZKCFHKBVSIMZ-UHFFFAOYSA-N

物化性质

• 熔点：
  232-233℃
• 沸点：
  490.7±55.0 °C(Predicted)
• 密度：
  1.37

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  88.1
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S36/37
• 危险类别码：
  R20/21/22

SDS

Name:	4-Amino-2-morpholino-5-pyrimidinecarbonitrile 97% Material Safety Data Sheet
Synonym:
CAS:	78318-43-1

Section 1 - Chemical Product MSDS Name:4-Amino-2-morpholino-5-pyrimidinecarbonitrile 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
78318-43-1	4-Amino-2-morpholino-5-pyrimidinecarbo	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 78318-43-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 229 - 231 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H11N5O
Molecular Weight: 205.22

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 78318-43-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Amino-2-morpholino-5-pyrimidinecarbonitrile - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRILES, SOLID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
IMO
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
RID/ADR
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 78318-43-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 78318-43-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 78318-43-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氨基-2-(4-吗啉基)-5-嘧啶甲腈 在 sodium hydroxide 、 potassium tert-butylate 、 双氧水 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 7-morpholin-4-yl-2-phenyl-3H-pyrimido[4,5-d]pyrimidin-4-one
  参考文献：
  名称：

  吡唑并[3,4-d]嘧啶和嘧啶并[4,5-d]嘧啶-4-酮衍生物的简便合成

  摘要：

  摘要 吡唑并嘧啶和嘧啶并嘧啶衍生物已显示出广泛的生物活性，例如作为 A1 腺苷受体、激酶插入域受体 (KDR)、劳斯肉瘤癌基因 (Src)、表皮生长因子受体 (EGFR)、抗增殖剂、二氢叶酸还原酶 (DHFR)。 )、抗微生物、抗真菌和脂质过氧化。由于这种广泛的活性，我们合成了吡唑并[3,4-d]嘧啶和嘧啶并[4,5-d]嘧啶-4-one衍生物。

  DOI：

  10.1080/00397910600773726
• 作为产物：
  描述：

  4-氨基-2-(甲基硫代)嘧啶-5-腈 在 间氯过氧苯甲酸 作用下， 以 四氢呋喃 为溶剂， 生成 4-氨基-2-(4-吗啉基)-5-嘧啶甲腈
  参考文献：
  名称：

  吡唑并[3,4-d]嘧啶和嘧啶并[4,5-d]嘧啶-4-酮衍生物的简便合成

  摘要：

  摘要 吡唑并嘧啶和嘧啶并嘧啶衍生物已显示出广泛的生物活性，例如作为 A1 腺苷受体、激酶插入域受体 (KDR)、劳斯肉瘤癌基因 (Src)、表皮生长因子受体 (EGFR)、抗增殖剂、二氢叶酸还原酶 (DHFR)。 )、抗微生物、抗真菌和脂质过氧化。由于这种广泛的活性，我们合成了吡唑并[3,4-d]嘧啶和嘧啶并[4,5-d]嘧啶-4-one衍生物。

  DOI：

  10.1080/00397910600773726

文献信息

• [EN] SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS<br/>[FR] THIOHYDANTOÏNES (HÉTÉROARYLMÉTHYL) SUBSTITUÉES UTILISÉES COMME MÉDICAMENTS ANTICANCÉREUX
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2011029537A1

  公开（公告）日：2011-03-17

  The invention relates to substituted (heteroarylmethyl) thiohydantoin compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, and their use for the preparation of medicaments for the treatment and/or prophylaxis of disorders, in particular of prostate cancer.

  这项发明涉及一般式（I）所述和定义的取代（杂环烷基）硫代恶唑酮化合物，以及它们的制备方法，它们用于治疗和/或预防疾病的用途，以及它们用于制备药物以治疗和/或预防疾病，特别是前列腺癌。
• Substituted (Heteroarylmethyl)thiohydantoins
  申请人：Lücking Ulrich

  公开号：US20120251551A1

  公开（公告）日：2012-10-04

  The invention relates to substituted (heteroarylmethyl) thiohydantoin compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, and their use for the preparation of medicaments for the treatment and/or prophylaxis of disorders, in particular of prostate cancer.

  本发明涉及一般式（I）所描述和定义的取代（杂环芳基甲基）硫脲化合物，以及它们的制备方法，它们的用途用于治疗和/或预防疾病，以及它们的用途用于制备用于治疗和/或预防疾病的药物，特别是前列腺癌。
• Schmidt, Hans-Werner; Koitz, Gerald; Junek, Hans, Journal of Heterocyclic Chemistry, 1987, vol. 24, p. 1305 - 1307
  作者：Schmidt, Hans-Werner、Koitz, Gerald、Junek, Hans

  DOI：——

  日期：——
• Kristen, Helmut; Raddatz, Marianne, Zeitschrift fur Chemie, 1981, vol. 21, # 3, p. 101
  作者：Kristen, Helmut、Raddatz, Marianne

  DOI：——

  日期：——
• KRISTEN H.; RADDATZ M., Z. CHEM., 1981, 21, NO 3, 101
  作者：KRISTEN H.、 RADDATZ M.

  DOI：——

  日期：——